Peregrine adds to anti-phospholipid technology platform

By Elaine Rigoli

Tampa, Fla., Sept. 15 - Peregrine Pharmaceuticals, Inc. said new research validates a second phospholipid drug target in its anti-phospholipid platform.

The data indicated that the new target, known as PE (or phosphatidylethanolamine), can be specifically targeted on tumor blood vessels for anticancer applications, similar to the activity of PS (or phosphatidylserine), the target for Peregrine's bavituximab program.

The company said these results open the door to the possibility that orally available agents such as peptides and potentially even small molecule drugs could eventually become second-generation drug candidates using Peregrine's technology.

Peregrine is a biopharmaceutical company based in Tustin, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.